Apnimed, Inc. (APMD)
| Market Cap | 663.18M |
| Revenue (ttm) | 115.12M +380.1% |
| Net Income | 163.58M |
| EPS | 8.49 |
| Shares Out | 41.63M |
| PE Ratio | 1.88 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 185,801 |
| Open | 15.32 |
| Previous Close | 15.10 |
| Day's Range | 15.09 - 16.28 |
| 52-Week Range | 13.88 - 35.29 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 50.33 (+215.95%) |
| Est. Earnings | Nov 20, 2026 |
About APMD
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Financial Performance
In 2025, Apnimed's revenue was $38.47 million, an increase of 380.12% compared to the previous year's $8.01 million. Losses were -$128.19 million, 15.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for APMD stock is "Strong Buy." The 12-month stock price target is $50.33, which is an increase of 215.95% from the latest price.
News
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late-stage clinical pharmaceutical company dedicated to the discovery, development and ...
Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026
CHEST-led panel to showcase data from the Phase 3 SynAIRgy and LunAIRo trials, exploring potential new paradigms for advancing OSA patient management CHEST-led panel to showcase data from the Phase 3 ...
Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercializatio...
Apnimed Quarterly report: Q2 2026
Apnimed has published its Q2 2026 quarterly earnings report on September 8, 2026.
Apnimed Earnings release: Q2 2026
Apnimed released its Q2 2026 earnings on September 8, 2026, summarizing the period's financial results.
Apnimed initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Josh Schimmer initiated coverage of Apnimed (APMD) with an Overweight rating and $60 price target The company’s Oxnimbi OSA therapy has delivered positive Phase 3 results and...
Apnimed initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Apnimed (APMD) with an Overweight rating and $60 price target
Apnimed initiated with an Outperform at Evercore ISI
Evercore ISI initiated coverage of Apnimed (APMD) with an Outperform rating and no price target Assuming 6.5% penetration into the non-obese segment of OSA patients who either outright refuse CPAP…
Apnimed initiated with an Outperform at LifeSci Capital
LifeSci Capital analyst Francois Brisebois initiated coverage of Apnimed (APMD) with an Outperform rating and $50 price target
Apnimed initiated with a Buy at BofA
BofA analyst Jason Gerberry initiated coverage of Apnimed (APMD) with a Buy rating and $41 price target Sole asset Oxnimbi, an oral therapy for obstructive sleep apnea with a February…
Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization...
Apnimed opens at $22.00, IPO priced at $16.00
Apnimed (APMD) priced 12M shares at $16.00. The deal size was increased to 12M shares from 10M shares of common stock and priced at the high-end of the $14.00-$16.00 range.
Apnimed 12M share IPO priced at $16.00
The deal size was increased to 12M shares of common stock from 10M shares of common stock and priced at the high-end of the $14.00-$16.00 range. BofA, Evercore ISI, Cantor…
Sleep apnea pill developer Apnimed targets $608 million valuation in US IPO
Late-stage drug developer Apnimed is targeting a valuation of up to $608 million in its initial public offering in the United States.
Sleep apnea pill maker Apnimed files for US IPO as biotech market revives
Apnimed, a late-stage clinical pharmaceutical company, filed for an initial public offering in the U.S. on Friday.
Apnimed IPO Registration Document (S-1)
Apnimed has filed to go public with an IPO on the NASDAQ